Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orion Trial: Long-term Safety and Tolerability of OPC-34712 (Brexpiprazole) as Adjunctive Therapy in Adults with Major Depressive Disorder
2011-001351-37Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brexpiprazole in major depressive disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Safety and tolerability of OPC-34712. Started Jul 2011; status: completed.
02
Drugs
brexpiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2011-001351-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001351-37.